BridgeBio Pharma (BBIO) Stock Price
BridgeBio Pharma Price
Revenue has compounded at 52.1% per year over the past 6 years to 502.08 M USD. BridgeBio Pharma's net margin stands at -145.3%, up from -806.9% several years earlier. Analysts set a median price target of 106.50 USD, implying 60.2% above the current price. Of 29 analysts, 26 rate the stock a buy — an overall Buy consensus.
BridgeBio Pharma stock price
BridgeBio Pharma business model & stock analysis
Frequently asked questions about BridgeBio Pharma
BridgeBio Pharma Inc is a biopharmaceutical company specializing in the development and commercialization of genetic medicines. The company aims to identify and advance therapies for diseases with clear genetic causes, leveraging its deep understanding of molecular pathways and human biology. BridgeBio Pharma Inc follows a diversified business model, which includes creating subsidiary companies focused on developing treatments for specific genetic diseases. These subsidiaries collaborate with academic institutions and industry partners to expedite the development of innovative therapies. By focusing on genetically driven diseases and utilizing a collaborative approach, BridgeBio Pharma Inc strives to bring transformative treatments to patients in need.
BridgeBio Pharma Inc is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of BridgeBio Pharma Inc in the market include companies such as Amgen Inc, Gilead Sciences Inc, Biogen Inc, and Vertex Pharmaceuticals Incorporated.
BridgeBio Pharma Inc is a leading pharmaceutical company specializing in the development and commercialization of targeted therapies for genetic diseases and cancers. Founded in 2015, BridgeBio Pharma Inc has rapidly grown into a prominent player in the biotechnology industry. The company's mission is to identify and advance transformative medicines that address the unmet needs of patients with genetically driven conditions. With its innovative pipeline of candidates, BridgeBio Pharma Inc aims to make a meaningful impact on patients' lives. By leveraging its deep expertise in genetics and drug development, the company is poised to revolutionize the treatment landscape for various rare diseases and oncology indications.
BridgeBio Pharma Inc has achieved several significant milestones since its inception. The company has successfully developed a diverse pipeline of investigative compounds across multiple therapeutic areas, including genetically defined diseases and cancers. BridgeBio Pharma has also formed strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its promising candidates. Additionally, the company has received regulatory approvals for several of its therapeutics and has successfully advanced them into clinical trials. These milestones highlight BridgeBio Pharma's commitment to addressing unmet medical needs and advancing innovative therapies for patients around the world.
BridgeBio Pharma Inc is primarily present in the United States.
BridgeBio Pharma Inc represents a commitment to innovative solutions and transformative therapies. Guided by a strong corporate philosophy, the company focuses on addressing unmet medical needs and improving patient outcomes. BridgeBio Pharma Inc pioneers in developing targeted medicines for genetic diseases and cancers. With their dedication to scientific excellence, they identify potential drug candidates and accelerate their development through collaborations and partnerships. By leveraging cutting-edge research and technological advancements, BridgeBio Pharma Inc aims to positively impact the lives of patients and families affected by rare genetic disorders.
Analysts currently set an average price target of 107.92 USD for the BridgeBio Pharma stock (median: 106.50 USD), implying +62.3 % versus the latest price. The consensus is based on 29 analyst ratings.
29 analysts currently rate the BridgeBio Pharma stock: 26 recommend buying, 3 holding and 0 selling. For 2026, analysts expect BridgeBio Pharma to generate revenue of 1.02 B USD and earnings per share of -2.72 USD.
Converted at the current exchange rate, the BridgeBio Pharma share trades at 59.38 EUR (66.50 USD).
The BridgeBio Pharma share (BBIO) is listed on 3 stock exchanges, including: NASDAQ (BBIO), München (2CL.MU), Düsseldorf (2CL.DU).
BridgeBio Pharma Inc. is a biotechnology company focused on developing drugs for rare diseases. The company was founded in 2015 and is based in Palo Alto, California. Its business model is based on identifying and developing therapy approaches for rare diseases. BridgeBio works closely with researchers, academics, and other biotech companies to develop innovative therapies. It has a strong pipeline of drug candidates in preclinical and clinical studies. Flagship products include Infigratinib for FGFR2-gene defined cholangiocarcinoma and BBP-265 for ACADVL deficiency. BridgeBio has partnerships with major pharmaceutical companies such as Pfizer and Roche. It focuses on rare diseases, taking advantage of the limited treatment options and strong need in these patient populations. The company is funded through investments from venture capital firms and public institutions. It had a successful IPO in June 2019, raising nearly $350 million for pipeline development and financing teams working on new therapies. Overall, BridgeBio's business model is centered on identifying and developing therapies for rare diseases, with a strong pipeline and partnerships in place.
The expected revenue of BridgeBio Pharma is 1.02 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of BridgeBio Pharma is -537.05 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of BridgeBio Pharma is currently -24.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the BridgeBio Pharma stock.
The price-to-sales ratio (P/S) of BridgeBio Pharma is currently 12.86. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the BridgeBio Pharma stock.
The Eulerpool Quality Score for BridgeBio Pharma is 3/10.
The ISIN of BridgeBio Pharma is US10806X1028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of BridgeBio Pharma is A2PLX7. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of BridgeBio Pharma is BBIO. The ticker symbol is used to trade BridgeBio Pharma shares on the stock exchange.
BridgeBio Pharma stock
BridgeBio Pharma Peer Group
BridgeBio Pharma Ticker
BridgeBio Pharma FIGI
All fundamentals and in-depth analysis of BridgeBio Pharma
Our stock analysis for BridgeBio Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BridgeBio Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.